Paclitaxel (Taxol®) for the treatment of lymphoma

Annals of Oncology

Volumn 8, Issue SUPPL. 1, 1997, Pages

  Younes, A ^a   Ayoub, J P ^a   Sarris, A ^a   North, L ^a   Pate, O ^a   McLaughlin, P ^a   Rodriguez, M A ^a   Romaguera, J ^a   Hagemeister, F ^a   Bachier, C ^a   Preti, A ^a   Cabanillas, F ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

lymphoma; paclitaxel

Indexed keywords

PACLITAXEL; ANTINEOPLASTIC AGENT;

ANTINEOPLASTIC ACTIVITY; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFICACY; DRUG RESPONSE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LYMPHOMA; MAJOR CLINICAL STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT OUTCOME; ARTICLE; DRUG ADMINISTRATION;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; DRUG ADMINISTRATION SCHEDULE; HUMANS; INFUSIONS, INTRAVENOUS; LYMPHOMA; PACLITAXEL;

EID: 0030627524     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/8.suppl_1.S129     Document Type: Conference Paper

References (16)

1. Rowinsky EK, Donehower RC. Paclitaxel (Taxol). N Engl J Med 1995; 332: 1004.
2. Arnal I, Wade RH. How does taxol stabilize microtubules? Curr Biol 1995; 5: 900.
3. Long BH, Fairchild CR. Paclitaxel inhibits progression of mitotic cells to G1 phase by interference with spindle formation without affecting other microtubule functions during anaphase and telephase. Cancer Res 1994; 54: 4355.
4. Wahl AF, Donaldson KL, Fairchild C et al. Loss of normal p53 function confers sensitization to taxol by increasing jGx/M arrest and apoptosis. Nat Med 1996; 2: 72.
5. Wilson WH, Chabner BA, Bryant G et al. Phase II study of paclitaxel in relapsed non-Hodgkin's lymphomas. J Clin Oncol 1995; 13: 381.
6. Younes A, Sarris A, Melnyk A et al. Three-hour paclitaxel infusion in patients with refractory and relapsed non-Hodgkin's lymphoma. J Clin Oncol 1995; 13: 583.
7. Lopes NM, Adams EG, Pitts TW et al. Cell kill kinetics and cell cycle effects of taxol on human and hamster ovarian cell lines. Cancer Chemother Pharmacol 1993; 32: 235.
8. Arbuck SG, Canetta R, Onetto N et al. Current dose and schedule issues in the development of paclitaxel (Taxol). Semin Oncol 1993; 20 (Suppl 3): 31.
9. Younes A, Ayoub JP, Hagemeister FB et al. No effect of 96-hour paclitaxel infusion in patients with relapsed non-Hodgkin's lymphoma refractory to a 3-hour infusion schedule. J Clin Oncol 1996; 14: 543.
10. Seidman AD, Hochhauser D, Yau TJ et al. 96-hour paclitaxel after prior short taxene infusion: Phase II pharmacokinetic and pharmacodynamic study in metastatic breast cancer. Proc Am Soc Clin Oncol 1995; 14: 151 (Abstr).
11. Wilson WH, Bert SL, Bryant G et al. Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer: A phase I/II trial of 96-hour infusion. J Clin Oncol 1994; 12: 1621.
12. Horwitz S, Lothstein L, Manfred J et al. Taxol: Mechanisms of action and resistance. Ann NY Acad Sci 1986; 466: 733.
13. Hanania EG, Deisseroth AB. Serial transplantation shows that early hematopoietic precursor cells are transduced by MDR-1 retroviral vector in a mouse gene therapy model. Cancer Gene Ther 1994; 1: 21.
14. Sarris A, Younes A, McLaughlin P et al. Cyclosporine A does not reverse clinical resistance to paclitaxel in patients with relapsed non-Hodgkin's lymphoma. J Clin Oncol 1996; 14: 233.
15. Tolcher AW, Cowan KH, Solomom F et al. Phase I crossover study of paclitaxel with r-verapamil in patients with metastatic breast cancer. J Clin Oncol 1996; 14: 1173.
16. Webster L, Linsenmeyer M, Millward M et al. Measurement of Cremophore EL following taxol: Plasma levels sufficient to reverse drug exclusion mediated by the multidrug resistant phenotype. J Natl Cancer Inst 1993; 85: 1685.